Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of High Doses of Both Pegylated Interferon Alfa-2a and Ribavirin for Retreatment of HIV-coinfected Patients With Liver Cirrhosis Due to HCV Genotype 1 or 4 Nonresponders to Previous Standard Therapy.

NCT01006031 is registered in ClinicalTrials.gov with Sociedad Andaluza de Enfermedades Infecciosas as lead sponsor.

NCT NCT01006031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01006031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of High Doses of Both Pegylated Interferon Alfa-2a and Ribavirin for Retreatment of HIV-coinfected Patients With Liver Cirrhosis Due to HCV Genotype 1 or 4 Nonresponders to Previous Standard Therapy.
Lead sponsor
Sociedad Andaluza de Enfermedades Infecciosas
Phase
Phase 2/3
Overall status
Completed
Start date
October 31, 2009
Completion date
December 31, 2011
Enrollment
25 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c virus, hiv infection, liver cirrhosis